NEW YORK (GenomeWeb News) – Qiagen and Exosome Diagnostics have inked a partnership to develop and commercialize co-branded kits to capture and process RNA and DNA from biofluid exosomes and other microvesicles, the companies said after the markets closed on Tuesday.

As part of the agreement, the companies will combine Exosome's proprietary exosome platform technology with select Qiagen consumables and automation platforms, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.